MVP Act
Sponsored By: Representative Guthrie, Brett [R-KY-2]
Introduced
Summary
value-based purchasing for Medicaid drugs would let States and manufacturers tie payments for drugs and biologicals to patient outcomes and change how Medicaid and Medicare count prices and rebates. The bill would create new reporting rules, legal protections, and guidance to support outcome-linked payment arrangements.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
State Medicaid value-based payment help
If enacted, the bill would create a federal exception to the anti-kickback law to allow manufacturers or third parties to pay States under value-based Medicaid deals when a patient fails to meet agreed outcomes after a covered outpatient drug. The HHS Office of Inspector General would need to write rules implementing that exception within 180 days after enactment. The bill would also require HHS to issue guidance within 180 days on how States and manufacturers can set up value-based deals for drugs given during inpatient hospital stays, including rules for fund transfers so patients treated outside their home State may be treated as if they got the drug in their State of residence.
Medicaid drug price reporting changes
If enacted, the bill would change how drug makers report prices for Medicaid value-based purchasing deals. You would have to count refunds, rebates, reimbursements, free goods, and withheld payments tied to patient outcome failures when reporting Average Manufacturer Price during the rebate period. For deals paid in installments, the total contractual price would be treated as paid in full in the first installment for rebate calculations. The bill would let manufacturers report multiple best-price points only if the same arrangement is offered to all States, and it would require HHS rulemaking within 180 days. The bill would also align Medicare’s average sales price rules to exclude certain VBP-linked payments when manufacturers elect the multiple best-price reporting.
Sponsors & CoSponsors
Sponsor
Guthrie, Brett [R-KY-2]
KY • R
Cosponsors
Auchincloss
MA • D
Sponsored 3/9/2026
Rep. Miller-Meeks, Mariannette [R-IA-1]
IA • R
Sponsored 3/9/2026
Joyce (PA)
PA • R
Sponsored 3/9/2026
Peters
CA • D
Sponsored 3/9/2026
Davis (NC)
NC • D
Sponsored 3/9/2026
Mullin
CA • D
Sponsored 5/11/2026
Ivey
MD • D
Sponsored 5/11/2026
Van Duyne
TX • R
Sponsored 5/11/2026
Rep. Carter, Earl L. "Buddy" [R-GA-1]
GA • R
Sponsored 5/12/2026
Rep. Dunn, Neal P. [R-FL-2]
FL • R
Sponsored 5/12/2026
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov